European Scientific Community Recognizes Core Science Behind ProtoKinetix’ AAGP™ Family of Molecules

PROTOKINETIX INC. (PKTX: OTCBB)
Vancouver, British Columbia, October 12, 2006

ProtoKinetix, Inc. is honoured to have their lead scientist, Dr. Geraldine Deliencourt, awarded the prestigious Francinov medal for scientific excellence, in the field of chemistry. The Francinov science and research awards are presented annually for the highest level of scientific research achievement administered under the guidance of L’Académie des Sciences. Several previous winners of the Francinov awards have gone on to win the Nobel Prize. The presentation of this award will be at the chateau de Versailles (the Palace of Versailles) on November 30, 2006.

Dr. John Todd is excited about the fact that PKTX’ core science has been validated at the highest level of the scientific community. This recognition will be presented on the world stage in front of many of the largest international corporations to ProtoKinetix’ chief scientist, Dr. Geraldine Deliencourt. For further information on the Francinov awards go to: www.francinov.net

About ProtoKinetix:
ProtoKinetix Inc is a Biotechnical Company dedicated to the development of a family of synthetic antifreeze glycoproteins (AAGP™) for human and veterinary medicine, the bio technology and cosmetic industries, and as a food additive. Using previously published research on native antifreeze proteins and antifreeze glycoproteins as a guide, and coordinating a vast pool of world recognized intellectual talent in a networked environment, PKTX is conducting rapid and meaningful research with a view to developing markets for this very useful family of molecules. Sign up for free automatic email news alerts at our new website at: www.protokinetix.com

The Private Securities Litigation  Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commision.

On behalf of the Board of Directors

Dr. John Todd – President

Company Office:   
Suite # 1500 885 West Georgia Street
Vancouver, BC V6C 3E8

Investor Contact:
ProtoKinetix
Blair Henderson
604-687-9887